Glycoprotein with reduced acetylation rate of sialic acid residues
The present invention relates to a method or process of producing a glycoprotein that interacts with, or acts as an agonist to, the erythropoietin receptor (EpoR), which glycoprotein has modified efficacy, wherein the method or process comprises the heterologous expression of said glycoprotein in a...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English |
Published |
09.09.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to a method or process of producing a glycoprotein that interacts with, or acts as an agonist to, the erythropoietin receptor (EpoR), which glycoprotein has modified efficacy, wherein the method or process comprises the heterologous expression of said glycoprotein in a suitable expression system, and wherein at least one step is provided that results in a reduced acetylation rate of sialic acid residues in the glycoprotein (Fig. 16). |
---|---|
Bibliography: | Application Number: AU20170297767 |